Navigation Links
EntreMed's MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial
Date:11/10/2008

Phase 2 Randomized Study Under Consideration

ROCKVILLE, Md., Nov. 10 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has met the primary endpoint for the efficacy portion of the open label Phase 1/2 study of MKC-1 in combination with pemetrexed (Alimta(R)) in non-small cell lung cancer patients.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

The Phase 1/2 study was designed to first evaluate a dose of MKC-1 to be used safely in combination with Alimta(R) to treat patients with advanced NSCLC. Patients were subsequently enrolled into the Phase 2 portion where the primary endpoint was tumor response. The primary endpoint has been met and EntreMed is considering options for further studies in NSCLC patients. Options include the continuation of the current single arm study or a randomized Phase 2 study in the same patient population.

MKC-1 is a novel, orally-active cell cycle inhibitor with in vitro and in vivo efficacy against a broad range of human solid tumor cell lines, including multi-drug resistant cell lines. Data from previous studies with MKC-1 demonstrate broad-acting antitumor effects, showing tumor growth inhibition or regression in multiple preclinical models, including paclitaxel-resistant models.

MKC-1 has been shown to inhibit mitotic spindle formation, prevent chromosome segregation in the M-phase (mitosis) of the cell cycle, and induce apoptosis. Furthermore, MKC-1 inhibits the Akt-mTOR signaling pathways, which may occur through inh
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. VNUS Medical Technologies, Inc. Announces the Hiring of Guido Smeets, MD, as Vice President of Clinical Research and Chief Medical Officer
2. Asenapine Meets Primary Endpoint in Long-Term Schizophrenia Relapse Prevention Trial
3. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
4. Teliks Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
5. The Science of Music Meets the Art of Medicine - ARIMM 3rd Annual Conference at IPFW, September 12-13, 2008
6. Atherotech VAP Cholesterol Test Meets Updated ADA, ACC Measurement and Treatment Guidelines for High Risk Patients
7. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
8. Axial Biotech Meets Major Scientific Milestones; Receives $6 Million Tranche of Series B Financing
9. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
10. World Think Tank on Type 1 Diabetes Meets in Miami
11. Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Freeslate, Inc ., the leading ... Lupin Limited, one of India’s top five pharmaceutical companies, ... System for high throughput solid form screening. ... a wide range of quality, affordable generic and branded ...
(Date:1/14/2014)... San Diego, CA (PRWEB) January 14, 2014 ... based on the products of cells grown under simulated ... an international license agreement with Suneva Medical, Inc. for ... media (CCM). , This agreement is an ...
(Date:1/14/2014)... DIEGO and BETHESDA, Md. ... are joining together with two institutes from the National ... reliable tools for bringing safer, more effective treatments to ... the National Center for Advancing Translational Sciences (NCATS) and ...
(Date:1/14/2014)... , Jan. 14, 2014   Kinaxis ®, provider of ... and sales and operations planning ( S&OP ) service, is ... Summit , which will be held at the Hilton San ... join Kinaxis customer Elisabeth Kaszas , Director of Supply ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... as the "holy grail" of nanoscience, researchers at the ... the first time used DNA to guide the creation ... dimensions measured in billionths of a meter). The ability ... functional materials that take advantage of the unique properties ...
... 30 Monogram,Biosciences, Inc., (Nasdaq: MGRM ) announced ... 7, 2008 at 4:30 p.m. (Eastern Time) to discuss,fourth ... for 2008.,The call will be hosted by Mr. William ... in the live teleconference, please call (877) 545-1409,or (719) ...
... (TSX: HBP / Frankfurt: WKN 918864), AURORA, ... that at the Company,s Annual General Meeting held ... resolutions presented by,management, appointing KPMG LLP as auditor, ... Slawomir Majewski, and Gordon Lickrish as,directors, and approving ...
Cached Biology Technology:DNA technique yields 3-D crystalline organization of nanoparticles 2DNA technique yields 3-D crystalline organization of nanoparticles 3Monogram Biosciences Announces Fourth Quarter 2007 Financial Results Conference Call 2Helix BioPharma shareholders vote in favour of management 2
(Date:7/9/2014)... delivered by Caesarean section have a different intestinal flora than ... why this is the case and what it means for ... Medical Sciences therefore decided to scrutinise the impact of birth ... of newborn mouse pups. , The study ... lower number of cells that strengthen the immune system, says ...
(Date:7/9/2014)... hunts in Indiana state parks have helped restore the ... by overabundant populations of white-tailed deer, a Purdue study ... associate professor of forest ecology, found that a 17-year-long ... in state parks has successfully spurred the regrowth of ... browsing deer. , Jenkins said that while hunting ...
(Date:7/9/2014)... (July 9, 2014) Emerging fungal pathogens pose ... parasitic group, causing population declines of amphibians, bats, ... University of South Florida published in the prestigious ... acquire behavioral or immunological resistance to a deadly ... , "Acquired resistance is important because it ...
Breaking Biology News(10 mins):Mouse study: Natural birth may strengthen the immune system 2Hunting gives deer-damaged forests in state parks a shot at recovery 2USF study: Amphibians can acquire resistance to deadly fungus 2
... an important discovery in the interdisciplinary study of split-brain research. ... left and right hemispheres. Split-brain research has been conducted ... processing is largely located in the left side of the ... an area processed by the right side of the ...
... between partners is a fundamental requisite in agricultural biotech ... from a four year study into what built or ... In a special supplement published in the UK-based journal ... from the Sandra Rotman Centre at the University Health ...
... been considered a major risk factor for cardiovascular disease. ... but the mechanisms of how arteries stave off hardening ... Perelman School of Medicine, University of Pennsylvania, Wistar Institute, ... the protein apolipoprotein E (apoE) plays a major role ...
Cached Biology News:UCSB scientists report 'new beginning' in split-brain research, using new analytical tools 2UCSB scientists report 'new beginning' in split-brain research, using new analytical tools 3UCSB scientists report 'new beginning' in split-brain research, using new analytical tools 4Study details essential role of trust in agricultural biotech partnerships 2Study details essential role of trust in agricultural biotech partnerships 3Study details essential role of trust in agricultural biotech partnerships 4Study details essential role of trust in agricultural biotech partnerships 5Study details essential role of trust in agricultural biotech partnerships 6Softening arteries, protecting the heart 2Softening arteries, protecting the heart 3
... The Cytomics FC 500 Series ... equipped with the most advanced ... Series delivers flexible testing, powerful ... features that help researchers optimize ...
... irreversibly crosslinked to protein G-agarose beads which ... from heart mitochondria. Also included are 2 ... immunocapture. ,The pyruvate dehydrogenase complex (PDH) immunocapture ... amounts of tissue. This facilitates the subsequent ...
... delivery using PULSin may be superior to ... unlike traditional transfection, with PULSin you can ... and time course of proteins in cells. ... more information than traditional RNA interference experiments. ...
... delivery using PULSin may be superior to ... unlike traditional transfection, with PULSin you can ... and time course of proteins in cells. ... more information than traditional RNA interference experiments. ...
Biology Products: